FOXP3 Polypeptide Mutations for T Cell Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune diseases are inadequate in enhancing and stabilizing the immunosuppressive effects of T cells, which are crucial for managing autoimmune responses.
Innovation Solution
The introduction of a nucleic acid sequence encoding a FOXP3 polypeptide and one or more transcription factors into T cells, along with a therapeutic gene product and/or a binding agent, to enhance their immunosuppressive functions, including nuclear localization and stabilization mutations, and the use of chimeric antigen receptors for targeted antigen binding.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If FOXP3 polypeptide is introduced into T cells to enhance immunosuppressive functions, then Treg cell activity is increased, but the stability and nuclear localization of FOXP3 polypeptide may be compromised
Solution Approach 1:
The patent applies parameter changes by introducing specific mutations into the FOXP3 polypeptide sequence to optimize its properties. Mutations such as L69A, L71A, L74A, L76A in the nuclear export sequence enhance nuclear localization, while mutations like S19A, S33A, S57A, S58A, S59A, T115A, S418D, and S422A improve stability by preventing degradation. These parameter changes directly resolve the contradiction by modifying the FOXP3 polypeptide to simultaneously achieve both enhanced stability and maintained immunosuppressive function.
Solution Approach 2:
The patent employs copying by introducing nucleic acid sequences encoding modified FOXP3 polypeptides into T cells. Rather than directly manipulating the endogenous FOXP3 gene, the invention creates copies with optimized sequences that contain the stability-enhancing and nuclear localization mutations. These copied sequences are integrated into the T cell genome or maintained as episomal elements, allowing the cells to produce stable, functional FOXP3 polypeptides with enhanced immunosuppressive capabilities.
2Reliability
If multiple nucleic acid sequences are introduced into T cells to enhance function, then T cell activity is improved, but the complexity of the treatment protocol increases
Solution Approach 1:
The patent applies merging by combining multiple functional elements into integrated nucleic acid constructs. Rather than separately introducing FOXP3 polypeptide, transcription factors, and therapeutic genes as independent components, the invention merges them into coordinated expression cassettes where multiple genes are expressed from linked nucleic acid sequences. This merging reduces protocol complexity by streamlining the introduction process while maintaining the synergistic effects of multiple functional elements.
Solution Approach 2:
The patent employs universality by designing nucleic acid sequences that can serve multiple functions simultaneously. The introduced constructs are engineered to express FOXP3 polypeptide, co-express transcription factors that enhance FOXP3 function, and potentially deliver therapeutic gene products all from integrated systems. This multi-functionality reduces the number of separate treatment steps needed while achieving comprehensive T cell enhancement.
Data Source
AI summary
This document relates to methods and materials for treating a mammal having an autoimmune disease. For example, materials and methods for producing a T cell comprising a FOXP3 polypeptide and one or more transcription factors are provided herein. Methods and materials for treating a mammal having an autoimmune disease comprising administering to a mammal having an autoimmune disease an effective amount of a T cell are also provided herein.